Table 4 The distrubution of received therapies in concordant and discordant results
From: Systemic therapy response evaluation in prostate carcinoma with [68Ga]Ga-PSMA-11 PET/CT
| Â | Result of [68Ga]Ga-PSMA-11 and serum PSA | Total | ||
|---|---|---|---|---|
Concordant | Discordant | |||
Received Treatment | First-line hormone therapy | 14 | 3 | 17 |
82.4% | 17.6% | 100% | ||
Docetaxel | 17 | 4 | 21 | |
81% | 19% | 100% | ||
Abiraterone | 2 | 1 | 3 | |
66.7% | 33.3% | 100% | ||
Enzalutamide | 2 | 1 | 3 | |
66.7% | 33.3% | 100% | ||
Cabazitaxel | 1 | 2 | 3 | |
33.3% | 66.7% | 100% | ||
[177Lu]Lu-PSMA-617 | 3 | 0 | 3 | |
100% | 0% | 100% | ||
Total | 39 | 11 | 50 | |
78% | 22% | 100% | ||